Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 22 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

11Total
Not Applicable (3)
Early P 1 (1)
P 2 (7)

Trial Status

Recruiting10
Not Yet Recruiting6
Unknown2
Active Not Recruiting2
Withdrawn1
Enrolling By Invitation1

Clinical Trials (22)

Showing 20 of 20 trials
NCT07562659Phase 2RecruitingPrimary

Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer

NCT07562503Phase 2RecruitingPrimary

Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer

NCT07562490Phase 2RecruitingPrimary

A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer

NCT07562711Phase 2RecruitingPrimary

Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer

NCT04084249Not ApplicableActive Not Recruiting

ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial

NCT07475923Withdrawn

Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

NCT07507916Phase 2Not Yet RecruitingPrimary

Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07136077Phase 2Recruiting

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

NCT06792786Not ApplicableRecruiting

A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring

NCT07478705Not ApplicableNot Yet Recruiting

Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging

NCT07394218Phase 2Recruiting

ctDNA-guided Treatment Decision-making

NCT07371247Early Phase 1Enrolling By Invitation

Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy

NCT07254156Not Yet Recruiting

A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer

NCT07176962Recruiting

A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening

NCT07121335Recruiting

SMC Radiation Oncology SABR Cohort for Oligometastasis

NCT05029869Active Not Recruiting

Monitoring Minimal Residual Disease in Gastric Cancer by Liquid Biopsy Study Description

NCT06287749Recruiting

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

NCT06649838Not Yet Recruiting

Customized Circulating Tumor DNA Testing for Cervical Cancer Recurrence Surveillance and Treatment Decisions

NCT06707974Not Yet Recruiting

Prognostic Study of Via Dynamic Change of dT-DNA in Drainage Fluid After Radical Prostatectomy

NCT06287723Not Yet Recruiting

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Scroll to load more

Research Network

Activity Timeline